Novartis raises drug sales forecast, plans new stock buybacks
Bio Pharma Dive
JULY 18, 2023
The pharma company, which will soon split off its generic drug unit, plans to repurchase up to $15 billion of its shares through the end of 2025.
130 
Pharma companies in Baddi
Creogenic Pharma
APRIL 15, 2023
India is a major player in the global pharmaceutical industry, accounting for almost 20% of the export volume of generic drugs worldwide. Please contact us at sales@creogenicpharma.com or call at +918264379214 SEND ENQUIRY [contact-form-7] The post Pharma companies in Baddi appeared first on Creogenic Pharma.
Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
California’s low-cost insulin plans receive $100m manufacturing boost
Pharmaceutical Technology
JULY 15, 2022
CivicaRx is a non-profit generic drug company producing affordable insulin biosimilars in collaboration with the Juvenile Diabetes Research Foundation (JDRF). Most of the US insulin market is controlled by three pharma companies: Sanofi, Eli Lilly, and Novo Nordisk. In-house manufacturing the norm.
In the News: October Regulatory and Development Updates
Camargo
NOVEMBER 11, 2020
In October, Antares Pharma licensed Ferring Pharmaceuticals’ Nocdurna® (desmopressin acetate) sublingual tablet , which was approved in 2018 for the same indication as Noctiva and has a boxed warning highlighting the same risks. Presumably, Antares’ long-established 90-person urology sales force can achieve pull-thru of this drug product.
European Commission vs Big Pharma, or profit vs access? Â
Drug Discovery World
MARCH 29, 2023
Regulatory data protection (RDP) period RDP refers to the time when generic drug makers cannot refer to an innovator drug’s data to obtain a marketing authorisation 2. This looks like it may change shape in the future for the region, if the proposal put forward by the commission is adopted.
Teva faces EU antitrust probe over MS drug Copaxone
pharmaphorum
MARCH 5, 2021
The European Commission has formally opened an antitrust investigation into Teva, which will assess whether the pharma company illegally delayed launches and use of generic versions of its blockbuster multiple sclerosis drug Copaxone. In the end it wasn’t enough and sales last year were $213 million, a fraction of the $4.3
Teva shares slide as it faces illegal kickback charges from US government
pharmaphorum
AUGUST 20, 2020
Shares in Teva were down sharply this week after the US Department of Justice filed a complaint that the company paid illegal kickbacks to patient groups to boost sales of its multiple sclerosis drug Copaxone (glatiramer). The allegation is that Teva’s subsidiaries Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc.
Let's personalize your content